22589-46-4

Basic information

• Product Name: methyl 2-(oxiran-2-ylmethoxy)benzoate
• CAS NO: 22589-46-4
• Molecular Formula: C₁₁H₁₂O₄
• Molecular Weight: 208.2106
• Mol File: 22589-46-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 321.5°C at 760 mmHg
• Flash Point: 141.8°C
• Density: 1.213g/cm³
• Vapor Pressure: 0.000297mmHg at 25°C
• Refractive Index: 1.536
• CAS DataBase Reference: methyl 2-(oxiran-2-ylmethoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(oxiran-2-ylmethoxy)benzoate(22589-46-4)
• EPA Substance Registry System: methyl 2-(oxiran-2-ylmethoxy)benzoate(22589-46-4)

Safety Data

• Hazardous Substances Data: 22589-46-4(Hazardous Substances Data)

Upstream product

• 584-08-7 potassium carbonate 
• 106-89-8 epichlorohydrin 
• 119-36-8 methyl salicylate 
• 69-72-7 salicylic acid 

Downstream Products

• 85850-35-7 2-[3-(4-Formyl-piperazin-1-yl)-2-hydroxy-propoxy]-benzoic acid methyl ester 
• 85850-41-5 2-{2-Hydroxy-3-[2-(5-nitro-pyridin-2-ylamino)-ethylamino]-propoxy}-benzoic acid methyl ester 
• 85850-21-1 2-[3-(2-Acetylamino-ethylamino)-2-hydroxy-propoxy]-benzoic acid methyl ester 
• 85864-51-3 methyl 2-[2-Hydroxy-3-[N-[1,1-dimethyl-2-(aminocarbonylamino)ethyl]amino]propoxy]benzoate 
• 85850-31-3 2-[3-(2-Ethoxycarbonylamino-1,1-dimethyl-ethylamino)-2-hydroxy-propoxy]-benzoic acid methyl ester 
• 85850-49-3 C₁₅H₂₅N₃O₆S 
• 85850-30-2 2-(3-{1,1-Dimethyl-2-[(morpholine-4-carbonyl)-amino]-ethylamino}-2-hydroxy-propoxy)-benzoic acid methyl ester 
• 85850-39-1 2-{3-[2-(4-Chloro-1-hydroxy-naphthalen-2-ylamino)-ethylamino]-2-hydroxy-propoxy}-benzoic acid methyl ester 
• 83019-57-2 methyl 2-<2-hydroxy-3-<<2-<<(phenylamino)carbonyl>amino>ethyl>amino>propoxy>benzoate 
• 87484-85-3 Methyl 2-[2-Hydroxy-3-[N-[2-[N-(4-methylphenylsulfonyl)amino]ethyl]amino]propoxy]benzoate Oxalate 

Relevant articles and documents

Synthesis, characterization, and anti-inflammatory activities of methyl salicylate derivatives bearing piperazine moiety

In this study, a new series of 16 methyl salicylate derivatives bearing a piperazine moiety were synthesized and characterized. The in vivo anti-inflammatory activities of target compounds were investigated against xylol-induced ear edema and carrageenan-induced paw edema in mice. The results showed that all synthesized compounds exhibited potent anti-inflammatory activities. Especially, the anti-inflammatory activities of compounds M15 and M16 were higher than that of aspirin and even equal to that of indomethacin at the same dose. In addition, the in vitro cytotoxicity activities and anti-inflammatory activities of four target compounds were performed in RAW264.7 macrophages, and compound M16 was found to significantly inhibit the release of lipopolysaccharide (LPS)-induced interleukin (IL)-6 and tumor necrosis factor (TNF)-α in a dose-dependent manner. In addition, compound M16 was found to attenuate LPS induced cyclooxygenase (COX)-2 up-regulation. The current preliminary study may provide information for the development of new and safe anti-inflammatory agents.

Novel compounds

The invention provides compounds of general formula (I) wherein Q, R, R2, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS

A method for the treatment of prophylaxis of cardiac disorders in a mammal, comprising administering to such mammal a short-acting β-blocking compound of the formula: STR1 wherein R may be lower alkyl, aryl, or aralkyl; n may be an integer from 0 to about 10; x may be an integer from 1 to 3; Ar may be substituted or unsubstituted aromatic; R. sub.1 may be lower alkyl, or aralkyl; and pharmaceutically accepted salts thereof. Novel compounds possessing short-acting β-adrenergic blocking activity are also disclosed.